Catalina Capital Group LLC Makes New $479,000 Investment in Thermo Fisher Scientific Inc. (NYSE:TMO)

Catalina Capital Group LLC purchased a new position in Thermo Fisher Scientific Inc. (NYSE:TMO) during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 824 shares of the medical research company’s stock, valued at approximately $479,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Avidian Wealth Solutions LLC raised its holdings in Thermo Fisher Scientific by 82.0% during the 1st quarter. Avidian Wealth Solutions LLC now owns 1,123 shares of the medical research company’s stock worth $652,000 after buying an additional 506 shares during the period. TFB Advisors LLC acquired a new stake in Thermo Fisher Scientific during the 1st quarter worth about $245,000. Mediolanum International Funds Ltd acquired a new stake in Thermo Fisher Scientific during the 1st quarter worth about $59,002,000. Larson Financial Group LLC raised its holdings in Thermo Fisher Scientific by 0.7% during the 1st quarter. Larson Financial Group LLC now owns 5,059 shares of the medical research company’s stock worth $2,940,000 after buying an additional 34 shares during the period. Finally, Callan Capital LLC acquired a new position in shares of Thermo Fisher Scientific in the 1st quarter valued at about $287,000. 89.23% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Evercore ISI dropped their target price on Thermo Fisher Scientific from $615.00 to $600.00 and set an “outperform” rating on the stock in a report on Tuesday, July 2nd. Jefferies Financial Group restated a “buy” rating and issued a $650.00 price objective (up previously from $600.00) on shares of Thermo Fisher Scientific in a report on Monday, June 3rd. Deutsche Bank Aktiengesellschaft increased their price objective on Thermo Fisher Scientific from $600.00 to $610.00 and gave the stock a “buy” rating in a report on Thursday, April 25th. HSBC increased their price objective on Thermo Fisher Scientific from $660.00 to $670.00 and gave the stock a “buy” rating in a report on Tuesday, April 30th. Finally, JPMorgan Chase & Co. increased their price objective on Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a report on Thursday, April 25th. Five analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and an average price target of $606.47.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 2,000 shares of the business’s stock in a transaction that occurred on Friday, April 26th. The stock was sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the transaction, the senior vice president now owns 13,083 shares of the company’s stock, valued at approximately $7,430,359.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $567.28, for a total transaction of $5,672,800.00. Following the completion of the transaction, the chief executive officer now directly owns 123,816 shares in the company, valued at approximately $70,238,340.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Michael A. Boxer sold 2,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, April 26th. The stock was sold at an average price of $567.94, for a total value of $1,135,880.00. Following the transaction, the senior vice president now owns 13,083 shares of the company’s stock, valued at $7,430,359.02. The disclosure for this sale can be found here. In the last quarter, insiders have sold 22,000 shares of company stock valued at $12,532,780. 0.34% of the stock is owned by insiders.

Thermo Fisher Scientific Trading Up 0.9 %

Thermo Fisher Scientific stock traded up $5.01 during mid-day trading on Wednesday, hitting $536.87. The stock had a trading volume of 1,658,312 shares, compared to its average volume of 1,542,160. The stock has a 50-day simple moving average of $570.09 and a two-hundred day simple moving average of $564.01. The stock has a market capitalization of $204.93 billion, a PE ratio of 34.44, a P/E/G ratio of 2.50 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 12 month low of $415.60 and a 12 month high of $603.82. The company has a current ratio of 1.70, a quick ratio of 1.33 and a debt-to-equity ratio of 0.68.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.70 by $0.41. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. The firm had revenue of $10.35 billion for the quarter, compared to analysts’ expectations of $10.14 billion. As a group, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 21.65 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, July 15th. Investors of record on Friday, June 14th will be given a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a yield of 0.29%. The ex-dividend date of this dividend is Friday, June 14th. Thermo Fisher Scientific’s dividend payout ratio is presently 10.01%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.